Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jun 11, 2021 11:59am
169 Views
Post# 33372521

RE:RE:RE:RE:RE:RE:RE:Cancer centers are enrolling

RE:RE:RE:RE:RE:RE:RE:Cancer centers are enrollingLet's not forget that while it may be THTX's first trial, it is being led  by MD Anderson/Dr. Meric-Bernstam and she's likely done 100's of these trials. I may be wrong, but I believe the trial results will be published under her name and probably Marsolais and the other lead participants in the clinics.  They have likely seen everything in these  trials and there's SOP's for dealing with the expected odd events.  I think they're lucky MD Anderson and Cedars Sinai agreed to lead as they are both one of the largest and best in the country.  I don't know the Wayne State one as well, but I would assume they are also top-notch.  I'm confident it's all running as planned and hopefully get confirmation of that.  In the fireside chat, all PL said was something like it's looking like the pre-clinical results. Let's get some data around that comment.

SPCEO1 wrote: I do not know what is going on with the phase I trial but here are some observations which may or may not be relevant:

1.) This is the first cancer trial in the history of TH. It would not be surprising if they did not get everything exactly perfect when we look back at decisions they made at a later date. 

2.) This is trailblazing work they are doing in cancer research. There are no doubt some blind corners they are going to have to turn. Accordingly, we should expect some bumps inthe road as the trial proceeds.
 
3.) It seemed to me the time period between Mr. Snyder's first and second dose was longerr than what I thought was likely. So, given his evident poor health going into the trial, some issue may have arisen that slowed the dosing regimen for him. And since he sadly passed away, it seems reasonable to assume that he may have been pulled from the trial before he ever recieved a third dose due to his deteriorating health situation. Just guessing, but it is possible this has delayed the phase I dose progression efforts some.

4.) MD Anderson has been recruiting for a while now. I have to believe they have been able to find a number of potential patients for the phase I and things aree progressing. So, maybe things are pretty much on track with it.

5.) Hopefully, TH will give us an update on the phase I on 6/21 after which we will know exactly where things stand and if time lines have been pushed back some or if everything is still on track. From the language they have used in their press release, it is not clear to me they will be giving us a phase I update, but hopefully they will. 

I don't think we should assume that the phase I trial will go completely smoothly. We should anticipate some bumps in the road but, even so, that should not undermine the ability to reach a successful conclusion.
 
 


<< Previous
Bullboard Posts
Next >>